Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) is expected to announce its earnings results after the market closes on Thursday, April 3rd. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $33.23 million for the quarter. Parties that wish to listen to the company's conference call can do so using this link.
Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last announced its earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Lifecore Biomedical Stock Up 1.1 %
Lifecore Biomedical stock traded up $0.08 during midday trading on Tuesday, hitting $7.12. 138,537 shares of the stock were exchanged, compared to its average volume of 217,922. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. The company has a 50 day moving average price of $6.15 and a two-hundred day moving average price of $6.22. The firm has a market cap of $263.43 million, a P/E ratio of -12.71 and a beta of 0.96. Lifecore Biomedical has a 1 year low of $3.68 and a 1 year high of $7.99.
Insider Buying and Selling
In related news, CEO Paul Josephs bought 17,000 shares of the business's stock in a transaction on Wednesday, January 8th. The shares were bought at an average cost of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the purchase, the chief executive officer now owns 559,717 shares of the company's stock, valued at $3,212,775.58. This represents a 3.13 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 32.20% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Separately, Stephens reissued an "equal weight" rating and issued a $6.00 price target on shares of Lifecore Biomedical in a report on Friday, January 3rd.
Check Out Our Latest Analysis on Lifecore Biomedical
Lifecore Biomedical Company Profile
(
Get Free Report)
Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.
Read More
Before you consider Lifecore Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifecore Biomedical wasn't on the list.
While Lifecore Biomedical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
